{"id":389331,"date":"2022-12-19T00:00:00","date_gmt":"2022-12-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0017-2022-biopharma-hepatocellular-carcinoma-disease-landscape-forecast-g7-2022\/"},"modified":"2026-03-31T10:35:36","modified_gmt":"2026-03-31T10:35:36","slug":"dlsfon0017-2022-biopharma-hepatocellular-carcinoma-disease-landscape-forecast-g7-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0017-2022-biopharma-hepatocellular-carcinoma-disease-landscape-forecast-g7-2022\/","title":{"rendered":"Hepatocellular Carcinoma | Disease Landscape &#038; Forecast | G7 | 2022"},"content":{"rendered":"<p>Hepatocellular carcinoma remains a challenging disease with a complex underlying etiology. While angiogenesis inhibitors including Nexavar (Bayer \/ Amgen), Stivarga (Bayer), Lenvima (Eisai \/ Merck &#038; Co.), Cabometyx (Exelixis \/ Ipsen \/ Takeda), and Cyramza (Eli Lilly) have been central to the treatment of advanced disease, the market is set to witness a substantial change within the next 10 years driven by the 2020 approval of Tecentriq (Roche \/ Genentech) plus bevacizumab, the FDA approval of Imfinzi plus Imjudo (AstraZeneca) and the anticipated entry of novel emerging immune checkpoint inhibitor-based combinations. The anticipated uptake of these premium-priced regimens and their expected label expansion into the untapped early-stage setting will drive robust growth of the hepatocellular carcinoma market, where identified unmet needs remain to offer further opportunities for effective therapy development.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What are the current therapies for hepatocellular carcinoma, and what are the main unmet needs?<\/li>\n<li>What is the size of market-relevant drug-treatable populations, and how will drug-treatment rates change over time?<\/li>\n<li>What is the expected market impact of recent and forecast drug approvals on the various subpopulations of hepatocellular carcinoma? What are interviewed experts\u2019 insights on key existing and emerging agents?<\/li>\n<li>What are the key factors driving or constraining market growth?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p>Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p>Primary research: 19 country-specific interviews with thought-leading medical oncologists.<\/p>\n<p>Key companies: Bayer HealthCare \/ Amgen \/ Onyx, Bristol Myers Squibb \/ Ono Pharmaceutical, Merck &#038; Co., Eisai, Exelixis \/ Ipsen, Eli Lilly, Roche \/ Genentech, AstraZeneca.<\/p>\n<p>Key drugs: Nexavar, Lenvima, Stivarga, Cabometyx, Cyramza, Avastin, Tecentriq, Opdivo, Yervoy, Keytruda, Imfinzi, Imjudo.<\/p>\n<p>Population segments in the market forecast: early-stage, first-line intermediate-stage, second-line intermediate-stage, first-line advanced-stage, and second-line advanced-stage hepatocellular carcinoma.<\/p>\n<p>Emerging therapies: Phase III\/PR: 4 drugs; coverage of select Phase I and Phase II products.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancement<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n<p>Additionally, Disease Landscape &#038; Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389331","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatocellular-carcinoma","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389331\/revisions"}],"predecessor-version":[{"id":576162,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389331\/revisions\/576162"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}